Skip to main
BCTX

BCTX Stock Forecast & Price Target

BCTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BriaCell Therapeutics Corp has received a significant boost in its financial resources by securing a non-dilutive $2 million grant from the US National Cancer Institute (NCI) to advance its Bria-PROS+ program into clinical stages. This funding will support the manufacturing of clinical supplies and facilitate the Phase 1/2a development for metastatic prostate cancer, further enhancing the company's portfolio of immunotherapies. Additionally, this grant will aid in accelerating the clinical development of Bria-OTS+, which builds on Bria-OTS, currently in a Phase 1/2 clinical trial, highlighting the company’s commitment to advancing innovative cancer therapies.

Bears say

BriaCell Therapeutics faces significant risks impacting its financial outlook, including potential safety signals from clinical programs and the possibility of lower-than-expected efficacy, which could hinder trial successes and overall product development. The company also anticipates a need for substantial additional financing of approximately $120 million through 2037, raising concerns about its ability to meet financial obligations while continuing ongoing research efforts. Furthermore, the presence of increased competition in the market and potential regulatory hurdles further complicate BriaCell's prospects, contributing to a cautious outlook on the stock's future performance.

BCTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BriaCell Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BriaCell Therapeutics (BCTX) Forecast

Analysts have given BCTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, BCTX has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BriaCell Therapeutics (BCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.